Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， <italic style="font-style: italic">β</italic>-TG and MPO Levels

DU Min; SHEN Hong; FENG Xiaoteng; WANG Yiru; MAO Meijiao; LIU Ping

doi:10.13422/j.cnki.syfjx.202201724

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， β-TG and MPO Levels

更新时间：2023-02-07

- Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， β-TG and MPO Levels
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 5, Pages: 150-157(2023)
- 作者机构：
  
  1.上海中医药大学附属龙华医院，上海 200032
  2.上海市徐汇区中心医院，上海 200031
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.202201724
  CLC： R22;R242;R2-031;R287
- Published：05 March 2023，
  
  Published Online：21 July 2022，
  
  Received：13 March 2022，
- 稿件说明：
扫描看全文
杜敏,沈虹,冯骁腾等.调心方治疗冠心病伴焦虑/抑郁患者临床疗效及对血清5-HT、 β-TG、 MPO水平的影响[J].中国实验方剂学杂志,2023,29(05):150-157.

DU Min,SHEN Hong,FENG Xiaoteng,et al.Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， β-TG and MPO Levels[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(05):150-157.
杜敏,沈虹,冯骁腾等.调心方治疗冠心病伴焦虑/抑郁患者临床疗效及对血清5-HT、 β-TG、 MPO水平的影响[J].中国实验方剂学杂志,2023,29(05):150-157. DOI： 10.13422/j.cnki.syfjx.202201724.

DU Min,SHEN Hong,FENG Xiaoteng,et al.Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， β-TG and MPO Levels[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(05):150-157. DOI： 10.13422/j.cnki.syfjx.202201724.

摘要

目的

研究调心方治疗冠心病伴焦虑/抑郁患者临床疗效及对血清5-羟色胺（5-HT）、

-血小板球蛋白（

-TG）及髓过氧化物酶（MPO）水平的影响。

方法

将66例诊断为冠心病伴焦虑/抑郁状态患者，随机分为调心方组和黛力新组，每组33例。在冠心病常规西药治疗的基础上，黛力新组同时予西药黛力新治疗，调心方组予中药调心方治疗。连续服药治疗8周，观察治疗前后各组患者临床疗效、患者健康问卷（PHQ-9）量表、广泛性焦虑（GAD-7）量表、西雅图心痛（SAQ）量表、心率变异性分析、血清5-HT、

-TG及MPO水平变化两组患者不良反应发生率。

结果

两组患者基线各项指标差异均无统计学意义，两组具有可比性。治疗8周后，调心方组的中医证候疗效总有效率87.88%（29/33），优于黛力新组的63.64%（21/33）（

=-2.653，

0.05）。与本组治疗前比较，治疗4、8周时，两组患者PHQ-9量表、GAD-7量表积分均明显下降（

0.05），治疗后两组间差异无统计学意义。与本组治疗前比较，治疗4、8周时，两组患者SAQ量表各维度积分均明显升高（

0.05）；与黛力新组比较，治疗后调心方组患者的躯体活动受限程度及心绞痛稳定状态两个维度积分明显升高（

0.05）。与本组治疗前比较，治疗后两组患者血清5-HT水平均明显升高，血清

-TG、MPO水平明显降低（

0.05）；与黛力新组比较，两组间差异无统计学意义。与本组治疗前比较，调心方组心率变异性时域指标R-R间期的总体标准差（SDNN）及R-R间期平均值标准差（SDANN）明显升高（

0.05）；与黛力新组比较，治疗后调心方组时域指标SDNN、SDANN明显升高（

0.05）。试验期间药物不良反应发生率调心方组明显低于黛力新组（

0.05）。所有患者研究过程中无临床不良事件发生。

结论

中药调心方能改善冠心病伴焦虑/抑郁患者临床症状，升高血清5-HT水平，降低血清

-TG、MPO水平，药物不良反应少且安全性高，具有较高临床价值，值得推广。

Abstract

Objective

To explore the clinical effect of Tiaoxin formula in the treatment of patients with coronary heart disease and anxiety/depression and its impact on serum levels of 5-hydroxytryptamine （5-HT），

β-

thromboglobulin （

-TG） and myeloperoxidase （MPO）.

Method

A total of 66 patients with coronary heart disease and anxiety/depression were randomly divided into the Tiaoxin formula group and Deanxit group， 33 cases in each group. Both groups were given fundamental western treatment for coronary heart disease. Additionally， the Deanxit group was treated with flupentixol and melitracen tablets and the Tiaoxin formula group was treated with Tiaoxin Formula. The treatment lasted 8 weeks. Before and after treatment， the changes of clinical efficacy， Patient Health Questionnaire （PHQ-9）， Generalized Anxiety Disorder （GAD-7） scale， Seattle Angina Questionnaire （SAQ）， heart rate variability， and serum 5-HT，

-TG and MPO levels， and incidence of adverse reactions in the two groups were observed.

Result

There was no significant difference in the baseline indexes of patients in the two groups， and thus the two groups were comparable. After treatment for 8 weeks， the total effective rate for traditional Chinese medicine （TCM） syndromes in the Tiaoxin Formula group was 87.88% （29/33） higher than 63.64% （21/33） in the Deanxit group （

=-2.653，

0.05）. Compared with those before treatment， the PHQ-9 and GAD-7 scores of the two groups were decreased at week 4 and 8 of treatment （

0.05）， and there was no statistical difference between two groups. And the SAQ dimension scores of the two groups were increased at week 4 and 8 of treatment （

0.05）. Compared with the Deanxit group， the Tiaoxin Formula group had elevation in two dimension scores： Physical limitation and angina stability （

0.05）. Compared with the conditions before treatment， the serum 5-HT level in the two groups were increased， while the

-TG and MPO levels were lowered （

0.05）， and there was no distinct difference between two groups. In addition， the standard deviation of normal-to-normal intervals （SDNN） and standard deviation of average normal-to-normal intervals （SDANN） of the heart rate variability in the Tiaoxin formula group were elevated after treatment （

0.05）， which were more significant than those of the Deanxit group （

0.05）. During the treatment period， the incidence of adverse drug reactions in the Tiaoxin formula group was lower than that in the Deanxit group （

0.05）， and no adverse events were observed in the two groups.

Conclusion

Tiaoxin formula was effective for the treatment of patients with coronary heart disease accompanied by anxiety and depression， which improved the clinical symptoms， increased serum 5-HT levels， and decreased serum

-TG and MPO levels， and had few adverse reactions and high safety for patients， showing a high clinical value.

关键词

调心方冠心病焦虑/抑郁5-羟色胺（5-HT）β-血小板球蛋白（β-TG）髓过氧化物酶（MPO）

Keywords

Tiaoxin formulacoronary heart diseaseanxiety/depressionserum 5-hydroxytryptamine （5-HT）serum β-thromboglobulin （β-TG）serum myeloperoxidase （MPO）

references

DENG B Y， CUI J G， LI C J， et al. Psychological status in 1083 hospitalized patients with coronary artery disease［J］. Chin J Cardiol， 2010，38（8）：702-705.

赵静思，郝应禄，李燕萍，等.双心医学研究现状［J］.临床荟萃，2021，36（1）：93-96.

DUPRE M E， NELSON A， LYNCH S M， et al. Socioeconomic， psychosocial and behavioral characteristics of patients hospitalized with cardiovascular disease［J］. Am J Med Sci，2017，354（6）：565-572.

TILLMANN T， PIKHART H， PEASEY A， et al. Psychosocial and socioeconomic determinants of cardiovascular mortality in Eastern Europe： A multicentre prospective cohort study［J］. PLoS Med，2017，14（12）：e1002459.

钟艳，杨建安.心血管康复治疗在老年冠心病患者中的应用效果［J］.中国民康医学，2018，30（13）：123-124.

李剑颖，魏素丽，徐亚辉，等.“心脏疾病”与“心理疾病”的相关性与治疗［J］.中医临床研究，2017，9（36）：10-11.

丁玥. 百合调虑汤治疗冠心病支架术后伴焦虑状态（气虚血瘀型）的临床疗效观察［D］.哈尔滨：黑龙江中医药大学，2020.

孙玉婵. 解郁通心方治疗稳定型心绞痛合并焦虑的双心疗效观察［D］.北京：中国中医科学院，2020.

侯季秋，史金玉，安莹，等.双心方治疗冠心病心绞痛合并抑郁状态临床观察［J］.河南中医，2019，39（2）：224-227.

WANG Y， LIU Y J， LI F E，et al. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology［J］. J Herbal Med， 2020， doi：10.1016/j.hermed.2019.100303http://dx.doi.org/10.1016/j.hermed.2019.100303.

苗静，姚福梅.疏肝解郁法对双心疾病患者的中医证候改善及预后［J］.中国中医药现代远程教育，2021，19（13）：60-62.

PINTER A， SZATMARI S J， HORVATH T， et al. Cardiac dysautonomia in depression heart rate variability biofeedback as a potential add-on therapy［J］. Neuropsychiatr Dis Treatt，2019，15：1287-1310.

VASSOU C， CHRYSOHOOU C， SKOUMAS J， et al. Irrational beliefs， depression and anxiety， in relation to 10-year cardiovascular disease risk： The attica epidemiological study［J］.Anxiety Stress Coping，2022， 7：1-15.

WANG L， CHEN J. Progress in studies on TLR4 signaling pathway and major depressive disorder［J］. J Central South Univ （Med Ed），2017，42（6）：725-729.

SCHMITZ S L， ABOSI O J， PERSONS J E， et al. Impact of mood on endothelial function and arterial stiffness in bipolar disorder［J］. Heart Mind （Mumbai），2018，2（3）：78-84.

TECCO J， MONREAL J， STANER L. Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients： An open multicenter study in Belgium and Luxembourg［J］. Psychiatr Danub，2011，23（Suppl 1）：S35-S42.

ALKHATIB Y， AKHTAR M A， KANAWATI M A， et al. Depression and metabolic syndrome： A narrative review［J］. Cureus，2022，14（2）：e22153.

中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等.稳定性冠心病诊断与治疗指南［J］.中华心血管病杂志，2018，46（9）：680-694.

郑筱萸. 中药新药临床研究指导原则［M］.北京：中国医药科技出版社， 2002.

陈晓虎，朱贤慧，陈建东，等.双心疾病中西医结合诊治专家共识［J］.中国全科医学，2017，20（14）：1659-1662.

SPERTUS J A， WINDER J A， DEWHURST T A， et al. Development and evaluation of the Seattle Angina Questionnaire： A new functional status measure for coronary artery disease［J］. J Am Coll Cardiol， 1995 Feb，25（2）：333-341.

刘淑红. 西雅图心绞痛量表（SAQ）中文译本的信度、效度、反应度［D］.天津：天津医科大学，2003.

CONWERSANO C. Common psychological factors in chronic diseases［J］. Front Psychol，2019，10：2727.

LICHTMAN J H， FROELICHER E S， BLUMENTHAL J A， et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome： Systematic review and recommendations［J］. Circulation， 2014，129（12）：1350-1369.

MAVRIDES N， NEMEROFF C B. Treatment of affective disorders in cardiac disease［J］. Dialogues Clin Neurosci， 2015，17（2）：127-140.

毛慧子，田洪阳，陶贵周.双心医学诊疗模式对冠心病合并焦虑抑郁患者的疗效［J］.锦州医科大学学报，2018，39（3）：37-40，47.

于瑞，牛琳琳，陈彦，等.中医药在双心医学领域的干预探讨［J］.世界中西医结合杂志，2015，10（12）：1748-1749，1766.

孙聪. 冠心病伴焦虑、抑郁状态及其中医证型的相关研究［D］.成都：成都中医药大学，2016.

吴晓真. 冠心病伴焦虑和抑郁状态中医证型分布状况及相关因素分析［D］.福州：福建中医药大学，2016.

苏翔，赵明芬.冠心病合并抑郁焦虑障碍的中医辨证分型和证素研究概况［J］.世界最新医学信息文摘，2019，19（6）：127-128.

刘锷，韩林涛，薛大权.瓜蒌薤白药对的研究进展［J］.湖北中医药大学学报，2014，16（6）：111-114.

高丽娜，崔元璐，延阔，等.丹参红花配伍研究进展［J］.中草药， 2016， 47（4）： 671-679.

戴鸣.加味酸枣仁汤治疗不稳定型心绞痛伴抑郁状态患者的疗效观察［J］.中医药导报，2014，20（6）：38-40.

张敏.中药黄酮成分抗抑郁治疗作用研究进展［J］.北华大学学报：自然科学版，2015，16（5）：617-620.

NDREPEPA G. Myeloperoxidase- bridge linking inflammation and oxidative stress with cardiovascular disease［J］. Clin Chim Acta，2019，493：36-51.

BALDUS S， HEESCHEN C， MEINERTZ T， et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes［J］. Circulation，2003，108（12）：1440-1445.

VONKANEL R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment： How strong is the evidence？［J］. Acta Psychiatr Scand，2004，110（3）：163-177.

刘云鹏. 血小板活化在急性冠脉综合征合并焦虑障碍中的发病机制及干预措施［D］.西安：西安医学院，2018.

黄月薪.中国人群5-HT2A受体基因T102C与精神失常患者关联性的评价［D］.广州：南方医科大学，2015.

ZAFAR M U， PAZYEPES M， SHIMBO D， et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression［J］. Eur Heart J，2010，31（13）：1573-1582.

IRENE L V， MARIBEL D R， JAMES G W， et al. Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake［J］. Cardiovasc Res，2009，84（2）：309-316.

黄宇.抑郁症与冠心病关联研究的进展［J］.中西医结合心血管病电子杂志，2018，6（10）：22-23.

JUAN S. Heart rate variability： A noninvasive electrocardiographic method to measure the autonomic nervous system［J］. Swiss Med Wkly，2004，134（35/36）：514-522.

BIGGER J T J， FLEISS J L， ROLNITZKY L M， et al. Frequency domain measures of heart period variability to assess risk late after myocardial infarction［J］. J Am Coll Cardiol，1993，21（3）：729-736.

BLASE K， VERMETTEN E， LEHRER P， GEVIRTZ R. Neurophysiological approach by self-control of your stress-related autonomic nervous system with depression， stress and anxiety patients［J］. Int J Environ Res Public Health， 2021，18（7）：3329.

VEITH R C， LEWIS N， LINARES O A， et al. Sympathetic nervous system activity in major depression： Basal and desipramine-induced alterations in plasma norepinephrine kinetics［J］.Arch Gen Psychiatry，1994，51（5）：411-422.

BHATTACHARYYA M R， WHITEHEAD D L， RAKHIT R， et al. Depressed mood， positive affect， and heart rate variability in patients with suspected coronary artery disease［J］. Psychosom Med，2008，70（9）：1020-1027.

CARNEY R M， FREEDLAND K E， VEITH R C， et al. Major depression， heart rate， and plasma norepinephrine in patients with coronary heart disease［J］. Biol Psychiatry，1999，45（4）：458-463.

CARNEY R M， FREEDLAND K E， STEIN P K， et al. Effects of depression on QT interval variability after myocardial infarction［J］.Psychosom Med，2003，65（2）：177-180.

WATKINS L L， BLUMENTHAL J A， DAVIDSON J R， et al. Phobic anxiety， depression， and risk of ventricular arrhythmias in patients with coronary heart disease［J］. Psychosom Med，2006，68（5）：651-656.

李金英. PHQ-9和GAD-7量表在功能性胃肠病患者精神心理评测的应用研究［M］.南宁：广西医科大学， 2018.

徐维芳，彭漪，陈柄全，等. GAD-7和PHQ-9自评心理测评量表评估心内科门诊患者焦虑、抑郁状态［J］. 世界最新医学信息文摘，2018，4（16）：12-14.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Coronary Heart Disease and Obstructive Sleep Apnea Syndrome： Interpretation and Reflection Based on Simultaneous Treatment of Heart and Lung in Traditional Chinese Medicine

Inflammatory Mechanism of Coronary Heart Disease and Intervention Strategies of Chinese Medicine Based on ''Phlegm，Stasis，Toxin'' Theory

Knowledge Graph Construction of Coronary Heart Disease Based on Traditional Chinese Medicine Diagnosis and Treatment Guidelines

Research on Diagnosis and Prescription System of Coronary Heart Disease with Syndrome Elements Based on Improved Transformer Algorithm

Mechanism of Blood-activating and Toxin-removing Method in Treatment of Coronary Heart Disease and Cognitive Dysfunction Based on Treating Different Diseases with Same Method

Related Author

LUO Binyu

ZHU Mengmeng

LI Yiwen

CUI Jing

LIU Yanfei

HUANG Luqi

LIU Yue

LIU Pei

Related Institution

China Center for Evidence-based Medicine of TCM， China Academy of Chinese Medical Sciences

National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine（TCM）， Xiyuan Hospital， China Academy of Chinese Medical Sciences

The First Hospital of Hunan University of Chinese Medicine

College of Traditional Chinese Medicine，Hunan University of Chinese Medicine

Guang'anmen Hospital，China Academy of Chinese Medical Sciences

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Clinical Effect of Tiaoxin Formula in Treatment of Patients with Coronary Heart Disease and Anxiety/Depression and Its Impact on Serum 5-HT， β-TG and MPO Levels

DOI：10.13422/j.cnki.syfjx.202201724

摘要

Abstract

关键词

Keywords

references